Cell Death and Disease (Aug 2024)

Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers

  • Sreyashi Bhattacharya,
  • Hannah L. Harris,
  • Ridwan Islam,
  • Sanika Bodas,
  • Navatha Polavaram,
  • Juhi Mishra,
  • Dipanwita Das,
  • Parthasarathy Seshacharyulu,
  • Achyuth Kalluchi,
  • Anirban Pal,
  • Manish Kohli,
  • Subodh M. Lele,
  • Michael Muders,
  • Surinder K. Batra,
  • Paramita M. Ghosh,
  • Kaustubh Datta,
  • M. Jordan Rowley,
  • Samikshan Dutta

DOI
https://doi.org/10.1038/s41419-024-06916-y
Journal volume & issue
Vol. 15, no. 8
pp. 1 – 18

Abstract

Read online

Abstract Resistance to the current Androgen Receptor Signaling Inhibitor (ARSI) therapies has led to higher incidences of therapy-induced neuroendocrine-like prostate cancer (t-NEPC). This highly aggressive subtype with predominant small-cell-like characteristics is resistant to taxane chemotherapies and has a dismal overall survival. t-NEPCs are mostly treated with platinum-based drugs with a combination of etoposide or taxane and have less selectivity and high systemic toxicity, which often limit their clinical potential. During t-NEPC transformation, adenocarcinomas lose their luminal features and adopt neuro-basal characteristics. Whether the adaptive neuronal characteristics of t-NEPC are responsible for such taxane resistance remains unknown. Pathway analysis from patient gene-expression databases indicates that t-NEPC upregulates various neuronal pathways associated with enhanced cellular networks. To identify transcription factor(s) (TF) that could be important for promoting the gene expression for neuronal characters in t-NEPC, we performed ATAC-Seq, acetylated-histone ChIP-seq, and RNA-seq in our NE-like cell line models and analyzed the promoters of transcriptionally active and significantly enriched neuroendocrine-like (NE-like) cancer-specific genes. Our results indicate that Pax5 could be an important transcription factor for neuronal gene expression and specific to t-NEPC. Pathway analysis revealed that Pax5 expression is involved in axonal guidance, neurotransmitter regulation, and neuronal adhesion, which are critical for strong cellular communications. Further results suggest that depletion of Pax5 disrupts neurite-mediated cellular communication in NE-like cells and reduces surface growth factor receptor activation, thereby, sensitizing them to docetaxel therapies. Moreover, t-NEPC-specific hydroxymethylation of Pax5 promoter CpG islands favors Pbx1 binding to induce Pax5 expression. Based on our study, we concluded that continuous exposure to ARSI therapies leads to epigenetic modifications and Pax5 activation in t-NEPC, which promotes the expression of genes necessary to adopt taxane-resistant NE-like cancer. Thus, targeting the Pax5 axis can be beneficial for reverting their taxane sensitivity.